P
HAE icon

Pitcairn’s Haemonetics HAE Stock Holding History

Pitcairn’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,770
Closed -$338K – 526
2020
Q2 		$338K Buy
3,770
+418
+12% +$42.2K 0.03% 318
2020
Q1 		$334K Buy
+3,352
New +$363K 0.04% 272
2018
Q2 		– Sell
-3,920
Closed -$287K – 543
2018
Q1 		$287K Sell
3,920
-2,141
-35% -$147K 0.03% 394
2017
Q4 		$352K Sell
6,061
-31
-0.5% -$1.63K 0.04% 338
2017
Q3 		$274K Sell
6,092
-482
-7% -$20K 0.03% 380
2017
Q2 		$260K Sell
6,574
-231
-3% -$9.49K 0.03% 371
2017
Q1 		$276K Sell
6,805
-203
-3% -$7.93K 0.03% 390
2016
Q4 		$282K Hold
7,008
– – 0.03% 389
2016
Q3 		$254K Buy
+7,008
New +$241K 0.03% 411

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pitcairn's HAE Position: Q3 2020 in Review

Pitcairn sold out of Haemonetics (HAE) in Q3 2020, closing a stake of 3,770 shares — an estimated $338K sold.

Pitcairn first reported a position in HAE in Q3 2016 and held it in 9 quarters. The position peaked at $352K in Q4 2017. 268 funds tracked by Wall St. Rank hold HAE as of Q3 2020.

  • Pitcairn reported no remaining Haemonetics position as of Q3 2020 after selling out during the quarter.
  • Pitcairn sold 3,770 Haemonetics shares in Q3 2020, an estimated $338K.
  • Pitcairn first reported a position in Haemonetics in Q3 2016 and held it in 9 quarters.
  • Pitcairn's Haemonetics position peaked at $352K in Q4 2017.
  • 268 funds tracked by Wall St. Rank held Haemonetics as of Q3 2020.

Based on Pitcairn's 13F filing for Q3 2020, filed 3 Nov 2020.